First-in-human Study of Interferon-y PET Imaging to Assess Response to Immunotherapy (NCT06439914)
IFN-y PET Imaging: Bench to Bedside
π©Ί Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to investigate the use of \[89Zr\]Zr-DFO-emapalumab as an IFN-Ξ³ PET imaging agent to detect lesions and response to therapy among treatment-naΓ―ve non-small cell lung cancer (NSCLC) patients. PET scans following the imaging agent will be completed prior to and about 30 days after starting immunotherapy.
Who can join: Review the eligibility criteria below.
Location: Karmanos Cancer Institute β Detroit, Michigan
Age range: 18 Years
π§ͺ Interventions in This Study
π "Do I Qualify?" β 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria β
π All Participating Trial Locations (1 Sites)
- Karmanos Cancer Institute β Detroit, Michigan
π Contact the Study Coordinator
Phone: (313) 576-8309
Email: violan@karmanos.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
π° Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA Β§ 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non Small Cell Lung Cancer
- The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance β Boston, Massachusetts
- A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer β Middletown, New Jersey
- Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC β Beverly Hills, California
- Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer β Columbus, Georgia
- Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease β Edmonton, Alberta
- A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer β Springdale, Arkansas
Explore by condition: All Non Small Cell Lung Cancer clinical trials
π‘ How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.